Karrer Urs, Wagner Markus, Sierro Sophie, Oxenius Annette, Hengel Hartmut, Dumrese Tilman, Freigang Stefan, Koszinowski Ulrich H, Phillips Rodney E, Klenerman Paul
Nuffield Department of Clinical Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford OX1 3SY, United Kingdom.
J Virol. 2004 Mar;78(5):2255-64. doi: 10.1128/jvi.78.5.2255-2264.2004.
CD8(+) T cells are critical for the control of many persistent viral infections, such as human immunodeficiency virus, hepatitis C virus, Epstein-Barr virus, and cytomegalovirus (CMV). In most infections, large CD8(+)-T-cell populations are induced early but then contract and are maintained thereafter at lower levels. In contrast, CD8(+) T cells specific for murine CMV (MCMV) have been shown to gradually accumulate after resolution of primary infection. This unique behavior is restricted to certain epitopes, including an immunodominant epitope derived from the immediate-early 1 (IE1) gene product. To explore the mechanism behind this further, we measured CD8(+)-T-cell-mediated immunity induced by recombinant MCMV-expressing epitopes derived from influenza A virus or lymphocytic choriomeningitis virus placed under the control of an IE promoter. We observed that virus-specific CD8(+)-T-cell populations were induced and that these expanded gradually over time. Importantly, these CD8(+) T cells provided long-term protection against challenge without boosting. These results demonstrate a unique pattern of accumulating T cells, which provide long-lasting immune protection, that is independent of the initial immunodominance of the epitope and indicates the potential of T-cell-inducing vaccines based on persistent vectors.
CD8(+) T细胞对于控制许多持续性病毒感染至关重要,如人类免疫缺陷病毒、丙型肝炎病毒、爱泼斯坦-巴尔病毒和巨细胞病毒(CMV)。在大多数感染中,早期会诱导产生大量CD8(+) T细胞群体,但随后会收缩,此后维持在较低水平。相比之下,已证明针对鼠巨细胞病毒(MCMV)的CD8(+) T细胞在原发性感染消退后会逐渐积累。这种独特行为仅限于某些表位,包括源自即刻早期1(IE1)基因产物的免疫显性表位。为了进一步探究其背后的机制,我们检测了由表达源自甲型流感病毒或淋巴细胞性脉络丛脑膜炎病毒表位的重组MCMV诱导的CD8(+) T细胞介导的免疫,这些表位置于IE启动子的控制之下。我们观察到诱导产生了病毒特异性CD8(+) T细胞群体,并且这些细胞随时间逐渐扩增。重要的是,这些CD8(+) T细胞无需加强免疫就能为抵御攻击提供长期保护。这些结果证明了一种独特的T细胞积累模式,即能提供持久免疫保护,且独立于表位的初始免疫显性,这表明基于持续性载体的T细胞诱导疫苗具有潜力。